Global Signifor Market Size By Type (0.3mg/ml, 0.6mg/ml), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Signifor Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.0 billion by 2031, growing at a CAGR of 7.5% during the forecast period (2023–2031). Signifor (pasireotide) is a somatostatin analog approved for the treatment of Cushing’s disease and acromegaly. The growing incidence of endocrine disorders, rising awareness among healthcare providers, and expanding usage of targeted therapies are key factors fueling market growth. In addition, the emergence of improved formulations and ongoing clinical research to extend indications are expected to further boost the global Signifor market.

Drivers:

Rising Prevalence of Cushing’s Disease and Acromegaly:

An increasing number of patients diagnosed with endocrine-related conditions is a primary growth driver. Cushing’s disease and acromegaly, though rare, require long-term treatment, boosting demand for effective solutions like Signifor.

Improved Diagnosis and Screening:

Advancements in diagnostic technologies and a growing emphasis on early detection of hormonal disorders have led to a higher treatment initiation rate, favoring market expansion.

Supportive Regulatory Environment:

Orphan drug designation and favorable reimbursement policies in key markets such as the U.S. and Europe are facilitating easier access to Signifor, thus contributing to market growth.

Restraints:

High Treatment Costs:

The cost of therapy with Signifor remains significantly high, which can limit accessibility, especially in low-income and uninsured patient populations.

Side Effects and Safety Concerns:

Long-term use of pasireotide can lead to adverse effects such as hyperglycemia and gastrointestinal disturbances. These safety concerns may affect patient compliance and hinder growth.

Opportunity:

Pipeline Expansion and Label Extension:

Ongoing clinical trials aimed at extending the therapeutic applications of pasireotide for other endocrine-related conditions provide a major opportunity for market players.

Emerging Markets Growth Potential:

Asia-Pacific and Latin America represent high-growth regions due to the rising healthcare expenditure, improved diagnosis rates, and increasing focus on rare disease treatment.

Market by System Type Insights:

The subcutaneous injection segment accounted for the largest share in 2023 due to ease of administration and better patient compliance. However, the long-acting release (LAR) segment is expected to witness the highest growth during the forecast period, supported by increased demand for convenient dosing schedules and extended efficacy.

Market by End-use Insights:

Hospitals held the largest market share in 2023, as most patients undergoing treatment for Cushing’s disease or acromegaly are initially managed in tertiary care settings. Specialty clinics and endocrine centers are expected to grow rapidly due to their focus on chronic disease management and personalized care.

Market by Regional Insights:

North America dominated the global Signifor market in 2023, accounting for the highest revenue share, driven by high disease awareness, well-established healthcare infrastructure, and early adoption of novel therapies. Europe followed closely, supported by strong research funding and patient advocacy. Asia-Pacific is anticipated to be the fastest-growing region, driven by increasing healthcare access and diagnostic improvements in emerging economies like China and India.

Competitive Scenario:

Key players in the Global Signifor Market include Novartis AG (original manufacturer), Recordati Rare Diseases Inc., Ipsen, and Pfizer Inc. These companies are focusing on expanding indications, gaining regulatory approvals, and strategic collaborations to strengthen their market position.

Recent Developments:

In 2023, Novartis initiated a Phase III trial evaluating Signifor for additional pituitary-related disorders.

In 2024, Recordati entered a licensing agreement to distribute Signifor in several Asia-Pacific countries.

In 2025, Ipsen announced data showing improved glycemic control with LAR formulations of pasireotide in diabetic patients with Cushing’s disease.

Scope of Work – Global Signifor Market

Key Market Developments:

2023: Novartis initiated a global Phase III trial for Signifor in ACTH-secreting pituitary adenomas.

2024: Recordati expanded Signifor’s reach in Asia-Pacific through licensing agreements.

2025: Ipsen published favorable real-world data supporting LAR formulations in specialty care settings.

FAQs:

1) What is the current market size of the Global Signifor Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Signifor Market?

The major growth driver is the rising prevalence of endocrine disorders such as Cushing’s disease and acromegaly.

3) Which is the largest region during the forecast period in the Global Signifor Market?

North America is expected to remain the largest regional market.

4) Which segment accounted for the largest market share in Global Signifor Market?

The subcutaneous injection segment held the largest share in 2023.

5) Who are the key market players in the Global Signifor Market?

Key players include Novartis AG, Recordati Rare Diseases Inc., Ipsen, and Pfizer Inc.